These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 26983334)

  • 1. [Comment by Prof. Dr. med Dirk Müller-Wieland. The therapeutic goal for blood sugar lowering in diabetes treatment].
    Müller-Wieland D
    Med Monatsschr Pharm; 2016 Feb; 39(2):63. PubMed ID: 26983334
    [No Abstract]   [Full Text] [Related]  

  • 2. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Edwards JL
    N Engl J Med; 2016 Mar; 374(11):1093. PubMed ID: 26981943
    [No Abstract]   [Full Text] [Related]  

  • 3. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Fischereder M; Schönermarck U
    N Engl J Med; 2016 Mar; 374(11):1092-3. PubMed ID: 26981942
    [No Abstract]   [Full Text] [Related]  

  • 4. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Sarafidis PA; Tsapas A
    N Engl J Med; 2016 Mar; 374(11):1092. PubMed ID: 26981941
    [No Abstract]   [Full Text] [Related]  

  • 5. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Zinman B; Lachin JM; Inzucchi SE
    N Engl J Med; 2016 Mar; 374(11):1094. PubMed ID: 26981940
    [No Abstract]   [Full Text] [Related]  

  • 6. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
    Rosenstein R; Hough A
    N Engl J Med; 2016 Mar; 374(11):1093-4. PubMed ID: 26981944
    [No Abstract]   [Full Text] [Related]  

  • 7. Cardiovascular Risk and Sodium-Glucose Cotransporter 2 Inhibition in Type 2 Diabetes.
    Ingelfinger JR; Rosen CJ
    N Engl J Med; 2015 Nov; 373(22):2178-9. PubMed ID: 26605932
    [No Abstract]   [Full Text] [Related]  

  • 8. Preventing cardiovascular events with empagliflozin: at what cost?
    Naci H; Basu S; Yudkin JS
    Lancet Diabetes Endocrinol; 2015 Dec; 3(12):931. PubMed ID: 26590682
    [No Abstract]   [Full Text] [Related]  

  • 9. Understanding EMPA-REG OUTCOME.
    Gilbert RE; Connelly KA
    Lancet Diabetes Endocrinol; 2015 Dec; 3(12):930-1. PubMed ID: 26590681
    [No Abstract]   [Full Text] [Related]  

  • 10. Understanding EMPA-REG OUTCOME.
    Muskiet MH; van Raalte DH; van Bommel EJ; Smits MM; Tonneijck L
    Lancet Diabetes Endocrinol; 2015 Dec; 3(12):928-9. PubMed ID: 26590679
    [No Abstract]   [Full Text] [Related]  

  • 11. Understanding EMPA-REG OUTCOME.
    Ceriello A; Genovese S; Mannucci E; Gronda E
    Lancet Diabetes Endocrinol; 2015 Dec; 3(12):929-30. PubMed ID: 26590680
    [No Abstract]   [Full Text] [Related]  

  • 12. Cardiac and Renovascular Complications in Type 2 Diabetes--Is There Hope?
    Ingelfinger JR; Rosen CJ
    N Engl J Med; 2016 Jul; 375(4):380-2. PubMed ID: 27331286
    [No Abstract]   [Full Text] [Related]  

  • 13. ACP Journal Club. In patients with type 2 diabetes and CV disease, empagliflozin reduced a composite of CV events at 3.1 years.
    Shekelle P
    Ann Intern Med; 2016 Jan; 164(2):JC2. PubMed ID: 26784492
    [No Abstract]   [Full Text] [Related]  

  • 14. [The cardiovascular outcome is critical].
    Stiefelhagen P
    MMW Fortschr Med; 2016 Feb; 158(3):68. PubMed ID: 27119710
    [No Abstract]   [Full Text] [Related]  

  • 15. Superiority trials: statistical trickery or mass blindness?
    Shafiq N; Malhotra S
    Postgrad Med J; 2016 Feb; 92(1084):118-9. PubMed ID: 26621824
    [No Abstract]   [Full Text] [Related]  

  • 16. In Patients with Type 2 Diabetes and CV Disease, Empagliflozin Reduces CV and All-Cause Mortality.
    Ebell MH
    Am Fam Physician; 2016 Mar; 93(5):410. PubMed ID: 26926979
    [No Abstract]   [Full Text] [Related]  

  • 17. [SGLT2 inhibition in type 2 diabetes. New study data for reducing cardiovascular risk].
    MMW Fortschr Med; 2015 Oct; 157(18):86-7. PubMed ID: 26985517
    [No Abstract]   [Full Text] [Related]  

  • 18. Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis.
    Scheen AJ
    Diabetes Metab; 2016 Apr; 42(2):71-6. PubMed ID: 26856453
    [No Abstract]   [Full Text] [Related]  

  • 19. London buses: A cardiovascular outcome trial equivalent?
    Grant PJ
    Diab Vasc Dis Res; 2016 Nov; 13(6):382-383. PubMed ID: 27543327
    [No Abstract]   [Full Text] [Related]  

  • 20. [Empagliflozin: an oral antidiabetic with documented positive effect on cardiac mortality].
    Zechmann S
    Praxis (Bern 1994); 2016 Mar; 105(6):349-50. PubMed ID: 26980688
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.